A role for LYNX2 in anxiety-related behavior by Tekinay, A.B. et al.
A role for LYNX2 in anxiety-related behavior
Ayse B. Tekinaya,1, Yi Nongb, Julie M. Miwaa, Ivo Lieberamc,d, Ines Ibanez-Tallona,e, Paul Greengardb,2,
and Nathaniel Heintza,2
aLaboratory of Molecular Biology, Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065; bLaboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, NY 10065; cDepartment of Neuroscience and dDepartment of Biochemistry and Molecular Biophysics,
Columbia University, New York, NY 10032; and eMax-Delbrück-Center for Molecular Medicine (MDC), 13092 Berlin, Germany
Contributed by Paul Greengard, December 23, 2008 (sent for review December 4, 2008)
Anxiety disorders are the most prevalent mental disorders in
developed societies. Although roles for the prefrontal cortex,
amygdala, hippocampus and mediodorsal thalamus in anxiety
disorders are well documented, molecular mechanisms contribut-
ing to the functions of these structures are poorly understood.
Here we report that deletion of Lynx2, a mammalian prototoxin
gene that is expressed at high levels in anxiety associated brain
areas, results in elevated anxiety-like behaviors. We show that
LYNX2 can bind to and modulate neuronal nicotinic receptors, and
that loss of Lynx2 alters the actions of nicotine on glutamatergic
signaling in the prefrontal cortex. Our data identify Lynx2 as an
important component of the molecular mechanisms that control
anxiety, and suggest that altered glutamatergic signaling in the
prefrontal cortex of Lynx2 mutant mice contributes to increased
anxiety-related behaviors.
anxiety  LYNX2  nicotinic  prefrontal cortex
Fear and anxiety are adaptive functions that help us survive,which when prolonged or intense can lead to anxiety disor-
ders. Anxiety disorders are the most prevalent psychiatric dis-
orders, costing more than $40 billion annually in the United
States (1, 2). Our knowledge of the biological basis of anxiety
disorders is based largely on studies of animal models of fear and
anxiety (3–6), and human brain imaging studies (7). That work
has implicated several brain structures in the regulation of
anxiety, including the amygdala, medial prefrontal cortex
(mPFC), mediodorsal thalamus (MDT), CA1 region of hip-
pocampus and the bed nucleus of stria terminalis (8). Lynx2 is a
member of a family of prototoxin genes that encode small
proteins expressed in distinct patterns in the brain that can
modulate neuronal nicotinic acetylcholine receptor (nAChR)
activity in vitro (9–11), and contribute to neuronal function and
viability in vivo (12). Interestingly, Lynx2 is expressed specifically
in many structures involved in the control of anxiety, including
the prefrontal cortex, the amygdala, the hippocampus and the
mediodorsal thalamus as well as in other regions such as dentate
gyrus and specific brainstem nuclei (www.stjudebgem.org).
Given the expression of Lynx2 in anxiety associated brain areas,
the ability of the LYNX family of proteins to modulate neuro-
transmitter receptors, and the fact that mood and anxiety
disorders are thought to be due to altered neurotransmission (13,
14), we sought to test the involvement of the Lynx2 gene in fear
and anxiety through studies of Lynx2 knockout (KO) mice.
Results
Loss of Lynx2 Has No Effect on Gross Motor Behavior or Sensory
Processing. Lynx2/ mice were produced using standard gene
targeting procedures in C57BL/6 embryonic stem (ES) cells (Fig.
1A). After crossing to a germline Cre recombinase expressing
line (15), we generated inbred C57BL/6 mice in which two exons
of Lynx2 gene were deleted. Deletion of these exons in genomic
DNA was demonstrated by Southern blot analysis (Fig. 1B). Loss
of Lynx2 mRNA expression in the brains of the knockout mice
was verified by in situ hybridization, as illustrated in Fig. 1C for
the prefrontal cortex and amygdala.
The growth rate and longevity of Lynx2/ mice were normal
compared with those in WT mice, and they did not display any
obvious anatomical abnormalities. Given the high levels of Lynx2
expression in the brain, a battery of tests was conducted to assess
whether loss of Lynx2 leads to alterations in behavior. To
determine whether there were any major motor abnormalities in
Lynx2/ mice, we first used the open-field exploration test. No
significant differences were noted between Lynx2/ and wild-
type (WT) mice in terms of distance moved, percentage of time
spent moving, the mean velocity of movement, or the time spent
in the center of the open field (thigmotaxis) [supporting infor-
mation (SI) Fig. S1]. Lynx2/ mice did not display any ataxia or
tremor, and normal sensory responses were observed in ear-
twitch and eye-blink reflexes (16), in the hotplate test, and buried
food assay (Fig. S1). These results establish that the Lynx2/
animals display grossly normal motor and sensory functions.
Lynx2/ Display Elevated Fear and Anxiety-Like Behaviors. The
failure to observe changes in thigmotaxis in Lynx2/ mice is
noteworthy, since thigmotaxis has been used as a test for
anxiety-like behaviors. However, given the high levels of Lynx2
expression in brain regions involved in anxiety, further tests were
conducted to assess whether loss of Lynx2 leads to alterations in
other anxiety-related behaviors. The light-dark exploration test
is based on the natural aversion of rodents to brightly illuminated
spaces, and it is thought to measure aspects of generalized
anxiety (17). Using this test, we observed that Lynx2/ (n  10)
animals spent less time in the light compared to WT (n  10)
mice (P  0.01) (Fig. 2A) and made fewer transitions to light
compartment (P  0.0001), suggesting an increased level of
generalized anxiety. As a second test for anxiety-like behaviors,
we used the social interaction test, which is based on the
tendency of mice to spend time with a novel mouse rather than
an empty cage. Highly anxious mice avoid this type of social
interaction, and prefer to remain alone (18). We observed that
Lynx2/ (n  8) mice, in contrast to WT (n  10) controls,
spend significantly less time (P  0.001) with the novel mouse
and less time sniffing and interacting with the novel mouse (P 
0.05), preferring to spend time in the empty compartment (Fig.
2D). Rodents also have an aversion to elevated open spaces that
is reflected in their behavior when placed on an elevated
plus-maze (19). In this test, Lynx2/ mice (n  10) made fewer
transitions to (P  0.05) and spent less time in the open arms
than WT mice (n  10) (P  0.05) (Fig. 2B). Finally, to measure
baseline anxiety levels and learning in Lynx2/ and WT mice,
we used a 3-day passive avoidance task (20). On Day 1, we placed
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the animals inside the light compartment to habituate the mice
to the apparatus and measured the latency to go into the dark
compartment upon elevation of the guillotine door that sepa-
rates the two compartments. We observed that Lynx2/ mice
(n  10) spent significantly more time than WT mice (n  10)
before they entered the mysterious dark compartment (P  0.05)
(Fig. 2C). On Day 2, mice were trained to associate the dark
compartment with a mild electric shock, and their learning
behavior was tested on Day 3. When we compared their latencies
to enter dark chamber on Day 2 and Day 3, we observed that
both Lynx2/ and WT mice displayed similar learning behavior
(Fig. S1). We conclude from these data that Lynx2/ animals
exhibit clear anxiety-like behaviors that are not prominent in
WT mice.
We next tested Lynx2/ mice for Pavlovian fear conditioning.
The mice were trained on Day 1 to associate a mild electric shock
to a tone, the conditioned stimulus (CS). The following day, the
mice were placed in the training environment without any
auditory cue, and their behavior observed as a measure of
contextual fear. In this test, Lynx2/ mice ‘‘froze’’ upon entry
into the chamber as often as WT mice (Fig. 2E). The mice were
then placed in a novel environment and the number of freezes
recorded both in the absence of the CS, and in response to the
CS. Lynx2/ mice (n  12) exhibited significantly more freezing
behavior to the tone than WT mice (n  12) during the CS (F
(1, 22)  11.6403, P  0.005), suggesting either an enhanced fear
response in Lynx2/ animals, or an enhancement of auditory-
cued-associative learning due to loss of LYNX2 (Fig. 2E).
LYNX2 Forms Stable Associations with nAChRs and Modulates Their
Function. It has been well documented that both nicotine and
nAChRs can influence anxiety-related behaviors (21, 22). The
Lynx family of prototoxin genes encode small Ly6 like molecules
related to snake venom alpha neurotoxins that are expressed in
the nervous system as glycophosphoinositol-linked cell surface
proteins (23). LYNX1 can modulate both the desensitization
kinetics and single channel conductance of nAChRs (10), and its
deletion in vivo leads to altered responses to nicotine (12). To
find out whether the effect of Lynx2 on anxiety-related behaviors
might be through an effect on nAChRs, we tested whether
LYNX2 can modulate nAChR activity.
As an initial test for the direct action of LYNX2 on nAChRs,
two types of experiments were conducted. First, we assayed the
nAChR binding activity of LYNX2 by co-immunoprecipitation
studies in HEK293 cells. As shown in Fig. 3A, LYNX2 can bind
to the widely expressed nAChR subtypes, 7, 42. The spec-
ificity of these interactions is demonstrated by the failure of
LYNX2 to form complexes with the co-expressed GRID2
glutamate receptor, and by the failure of the closely related
LY6H protein to form complexes with any of the receptors
assayed. In separate experiments, we have observed that LYNX2
can also bind to 44 and muscle nAChRs, but that it does not
bind to 22 receptors (data not shown). From these data it is
evident that LYNX2 and LYNX1 binding to nAChRs is specific
and similar, although these two proteins are expressed in distinct
neuronal populations.
To determine whether LYNX2 interactions with AChRs could
alter their properties, we measured macroscopic currents elicited
by acetylcholine (ACh) using two-electrode voltage clamp re-
cordings in Xenopus oocytes expressing 42 nAChRs alone, or
together with LYNX1, LYNX2 and LY6H. In all cases, upon
application of ACh, inward currents peaked within 1 second and
then decayed with a biphasic profile to a steady plateau. De-
sensitization was measured by fitting two exponential equations
to the desensitization currents during ACh application and
calculating the fast (Fig. 3C) and slow (Fig. 3D) time constants
as previously described (10). In oocytes co-expressing either
LYNX1 or LYNX2, the ACh evoked-responses showed a faster
Fig. 1. Map of Lynx2/ targeting construct, Southern Blot analysis confirming the deletion of Lynx2 gene and in situ hybridization on Lynx2/ and WT brain
sections with Lynx2 probe. (A) Map of the targeting construct used to generate Lynx2-conditional KO mice. These mice were bred to EIIa::cre mice to generate
the Lynx2-null-mutant mice, in which exons 1 and 2 and the neo cassette were deleted. (B) Southern Blot analysis of the genomic DNAs of KO, heterozygous and
WT mice. (C) In situ hybridization on Lynx2/ and WT brain sections with Dig-labeled Lynx2 probe. Prefrontal cortex, hippocampus, amygdala, and mediodorsal
thalamus are shown. BLA, basolateral amygdala; MDT, mediodorsal thalamus.
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desensitization compared to oocytes expressing either 42
alone or co-injected with LY6H. As shown in Fig. 3C, the
average value for the fast time constant is significantly less in
oocytes co-expressing LYNX1 and LYNX2, and is not affected
in oocytes co-expressing LY6H. No difference was observed in
the slow time constant. Faster desensitization kinetics may
reflect differences in ligand sensitivity, as we have observed
when LYNX1 associates with 42 receptors (10), and con-
versely in Lynx1/ neurons (12). To address this point, we
performed dose-response experiments with ACh in 42 oo-
cytes with or without LYNX2. Dose-response curves, obtained
by normalizing the peak amplitudes at each ACh concentration
to the maximal peak amplitude at 1 mmol/l ACh, revealed a shift
of 20-fold toward higher ACh concentrations in the presence
of LYNX2 (42 EC50  1.2 mol/l, 42LYNX2 EC50  21
mol/l) (Fig. 3E). We conclude that LYNX2 can directly interact
and modulate nAChRs in vitro, and suggest that this interaction
may provide a mechanistic underpinning for the behavioral data
discussed above.
Altered Responses to Nicotine in Lynx2/ Mice. Taken together, the
behavioral and biochemical studies we report above suggest that
loss of LYNX2 could result in increased fear and anxiety due to
enhanced nAChR activity in cells that participate in circuits
controlling these behaviors. It has been proposed that enhanced
activation of medial prefrontal cortex (mPFC) by inputs from the
mediodorsal thalamus (MDT) might be involved in the control
of fear and anxiety (24). Furthermore, activation of nicotinic
receptors in preterminals projected from MDT to mPFC can
enhance glutamate release to layer V neurons (25). Since Lynx2
is expressed at high levels in the MDT, we reasoned that
measurements of sEPSCs in layer V pyramidal neurons might
reveal altered glutamate release in response to enhanced
nAChR activity in Lynx2/ mice. To test this idea, we per-
formed whole cell recordings in the layer V pyramidal neurons
in mPFC brain slices. When we compared the frequencies and
amplitudes of sEPSCs, we observed no significant difference
between WT and Lynx2/ mice (Fig. 4A).
We then examined the responses to nicotine in WT and
Lynx2/ mice. Consistent with previous reports (25), the fre-
quency of sEPSCs in layer V pyramidal neurons in mPFC was
significantly increased by application of 10 mol/l nicotine (Fig.
4B). This increase was blocked by TTX, suggesting that activa-
tion of sodium channels in presynaptic terminals is required for
this effect. The effects of 10 mol/l nicotine application were
also blocked by the nAChR antagonist Dihydro--erythroidine
hydrobromide (10 mol/l); implicating the activation of high
affinity nAChRs in this effect. These results are consistent with
previous reports demonstrating that high affinity 42nAChRs
located in the thalamocortical projections are involved in nico-
tine induced increases in sEPSCs in layer V pyramidal cells in
mPFC (25). Since our results demonstrate that LYNX2 can
modulate the sensitivity of nAChRs to nicotine in vitro, we
decided to test whether there are any differences in sEPSCs
between WT and Lynx2/ mice at lower concentration of
nicotine. We found that 300 nmol/l nicotine application in-
creased sEPSC frequency in both WT and Lynx2/ mice (Fig.
4 C and D). Interestingly, the response to nicotine was signifi-
cantly more enhanced in Lynx2/ mice than in WT controls:
nicotine (300 nmol/l) caused a 1.84  0.22 fold increase of
sEPSC frequency in Lynx2/mice (Fig. 4D, n  11 cells, 5 mice)
compared to 1.31  0.10 fold increase of sEPSC frequency in
Fig. 2. Lynx2/ mice have elevated fear and anxiety-like behavior. (A) In light-dark box test, Lynx2/ mice spent less time in light compartment (P  0.01)
and made less number of transitions to the light than WT mice (P  0.0001), showing elevated anxiety-like behavior. (B) In elevated plus-maze test, Lynx2/
mice spent less time in open arms (P  0.05) and made less transitions to the open arms than WT mice (P  0.05). (C) On Day 1 of passive avoidance test, Lynx2/
mice spent significantly more time than WT mice before they entered the dark compartment (P  0.05). (D) In social interaction test, KO mice spent less time
in a compartment with a stranger mouse (P  0.001) and spent less time sniffing and interacting with the stranger mouse than WT mice (P  0.05). (E) In fear
conditioning test, during audio-conditioned learning task, Lynx2/ mice froze more times than WT mice (P  0.01).








WT mice (Fig. 4D, n  11 cells, 5 mice) (P  0.05). Given the
in vitro actions of LYNX2 on nAChRs, and the high levels of
expression of Lynx2 in MDT, our data suggest that the increased
sensitivity of mPFC layer V neurons to nicotine in Lynx2/ mice
may result from release of inhibition by LYNX2 on nAChRs due
to the null mutation in these mice. As a consequence of the
enhanced nAChR activation we have observed in layer V
neurons of the mPFC, one might expect supranormal activation
of the basolateral amygdala by the mPFC, contributing to the
increased fear and anxiety-like behaviors documented in the
Lynx2/ mice.
Discussion
Our data establish several important findings regarding the role
of the Lynx2 gene in vivo. First, Lynx2/ mice demonstrate
increased anxiety-like behaviors as measured by three indepen-
dent rodent assays of anxiety and increased conditioned fear.
Second, binding of LYNX2 to nAChRs in vitro results in
increased receptor desensitization and decreased affinity for
acetylcholine. Consequently, loss of LYNX2 is predicted to
cause an increase in nAChR activity in Lynx2 expressing neu-
rons. Third, deletion of the Lynx2 gene results in increased
glutamatergic activity in response to nicotine in layer V neurons
of the mPFC. Taken together, these data suggest that Lynx2 has
an important and specific role in setting cholinergic tone in cells
known to participate in the control of anxiety. Furthermore,
when compared with previous studies of LYNX1, these data also
establish that the LYNX family of small modulator proteins,
while biochemically similar, subserve quite different and impor-
tant biological functions in vivo.
The behavioral consequences of Lynx2 deletion are interesting
with respect to previous studies of fear and anxiety. Results from
the light-dark box assay, the social interaction test, and the
elevated plus-maze all indicate an increase in generalized anxiety
levels in the mutant mice. Although the basolateral amygdala
(BLA) has been implicated in both anxiety and fear, the neu-
roanatomical relationships between these emotions are not
completely understood. Because a wide variety of studies have
shown that the BLA is required for auditory fear conditioning
responses and Lynx2 is heavily expressed in BLA, we also tested
Lynx2/ mice for fear conditioning paradigm. Although en-
hanced freezing to tone in fear conditioning tests in Lynx2/
mice might also be related to an increase in generalized anxiety,
enhanced associative learning during the fear conditioning task
could also explain this phenotype. Given the ability of LYNX2
to bind to and modulate nAChRs, we believe that the behavioral
effects of LYNX2 deletion may result from alterations in nAChR
function in cells participating in anxiety-related circuits. For
example, the glutamatergic circuitry from MDT to mPFC to
BLA has been implicated in the regulation of anxiety-related
behaviors (24). We have demonstrated here that nicotine acts
through high affinity nAChRs to increase glutamate release
from presynaptic terminals in the mPFC, and that loss of LYNX2
leads to increased glutamatergic activity. Given previous studies
demonstrating that high affinity nAChRs are present in presyn-
aptic terminals from the MDT to the mPFC (25), and the high
expression of Lynx2 in the MDT, the most parsimonious inter-
pretation of our results is that loss of LYNX2 in the MDT results
in elevated nAChR activity in thalamocortical neurons, resulting
in enhanced release of glutamate from these terminals. We
propose that the consequent increased activity of layer V
neurons in mPFC of Lynx2/ mice contributes to the elevation
in anxiety-related behaviors in these mice.
Direct comparisons between our results and previous studies
implicating nAChR activity in the control of anxiety are difficult
because of the large numbers of receptor subtypes and their
complex expression patterns in the brain. Nevertheless, it is well
established that nicotine and nAChRs can impact anxiety levels
Fig. 3. LYNX2 stably associates with nAChRs and enhances the desensitiza-
tion and decreases the ACh sensitivity of nAChRs. (A) Membrane extracts from
HEK293 cells expressing 7-LYNX2, 42-LYNX2, 42-LY6H, and GRID2-
LYNX2 were analyzed. The first lane in each blot shows a sample of the
membrane extract input and is indicated with letter I. The second lane in each
blot contains the immunoprecipitation fractions incubated with an antibody.
The upper blots show that 7 (52 kDa), 4 (69 kDa) and 2 (45 kDa)
subunits immunoprecipitated with 7 and 4 antibodies respectively. LYNX2
was also detected with anti-flag antibody in the IP fraction (15–20 kDa),
demonstrating that LYNX2 form stable complexes with both 7 and 42
nAChRs, whereas LY6H did not IP with 42 nAChRs (lower blots). LYNX2 did
not form stable complexes with GRID2 (114 kDa) receptor when immuno-
precipitated with GRID2 antibody. (B) Representative recordings of voltage-
clamped oocytes expressing 42 nAChRs alone, or in combination with
LYNX1, LYNX2, and LY6H. The inward currents were evoked by 20-second
periods of superfusion (horizontal calibration bar) with external saline con-
taining 1 mmol/l ACh. Oocytes coexpressing 42 nAChRs with either LYNX1
or LYNX2 showed a significantly faster initial desensitization immediately
after the peak response upon agonist application. Co-expression of LY6H had
no effect on the desensitization kinetics. (C and D) Bar graphs representing the
values of the fast and slow time constants obtained as previously described (10).
In oocytes coexpressing 42 nAChRs with either LYNX1 or LYNX2, the fast time
constant (C) is significantly faster, whereas the slow time constant during the
second phase remained the same (D). Both constants are unaffected in oocytes
coexpressing ly6h. (E) Dose-response curves for ACh in oocytes expressing 42
(triangles) and 42 nAChRs co-expressing LYNX2 (circles). Each plotted value is
the mean  SEM of 5 oocytes. The normalized peak amplitudes (I/Imax) at each
indicated ACh concentration were fitted to the Hill equation: I/Imax[ACh]nH/
([ACh]nHEC50)nH (drawn lines). The fitted parameters were EC50  1.2 mol/l for
42, 21 mol/l for 42 LYNX2, nH  0.55 in both cases.
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in both humans and rodents (14, 26). In humans, although
smokers generally accept nicotine as an anxiolytic (27), nicotine
was shown to have an anxiogenic effect in several studies (28, 29).
Furthermore, both genetic background and genetic perturba-
tions of nicotinic receptors in rodents result in variations in
anxiety-related phenotypes (21, 30, 31).
Although the effects of LYNX2 loss in layer V pyramidal
neurons in mPFC are likely to be mediated by high affinity-42
receptors, our in vitro data suggest that LYNX2 may modulate
the activities of several nAChR types. We expect, therefore, that
the actions of LYNX2 may be mediated by several different
nAChRs, so long as they are co-expressed with LYNX2. Thus,
at each site of anxiety-related circuitry where Lynx2 is expressed,
the precise mechanisms by which LYNX2 contributes to the
regulation of anxiety may differ. Given these complexities,
further cell specific genetic studies of LYNX2 and its impact on
anxiety-related behaviors may help in the identification of
specific cell types controlling anxiety.
Materials and Methods
Cloning. Lynx2 cDNA was subcloned into pBluscript-SK for in situ hybridization
probe. Ly6 domains and GPI anchorage sites and signals of Lynx1, Lynx2, and
Ly6h were subcloned into pFlag-CMV-1. cDNAs encoding nAChR 4, 2, 7, 4,
1, 1, , and  subunits were kind gifts from Jerry A. Stitzel, Marc Ballivet and
José Ramirez-LaTorre. They were subcloned into pCS2 in fusion with flag
tags and used for IP and in vitro transcription experiments. cDNAs encoding
Lynx1, Lynx2, and Ly6h were also subcloned into pCS2 and used for in vitro
transcription experiments. The expression plasmid for Grid2 was provided by
Zhenyu Yue.
In Situ Hybridization. Adult brain sections were prepared as described (32).
Digoxigenin (Dig-) labeled riboprobe was transcribed using 2 mol/l Dig-NTP
(Boehringer-Mannheim) in the transcription reaction. (Please see SI Materials
and Methods for details.)
Expression and IP from HEK293T Cells. HEK 293T cells were transfected by
calcium phosphate precipitation with the expression vectors containing the
cDNAs of Lynx1, Lynx2, Ly6h, 7 nAChR, Flag-tagged 1, 4, 2, 4,  and 
Fig. 4. Lynx2 null mutation enhances the ability of nAChR stimulation to increase sEPSCs frequency compared to WT mice in layer V pyramidal neurons in mPFC.
(A) Bar graphs show the mean sEPSC frequency (left) and amplitude (right) in WT and Lynx2/ mice layer V pyramidal neurons (WT: 6 mice, 12 cells; Lynx2/:
6 mice, 14 cells, P  0.05). (B) Representative traces showing the effects of 10 mol/l nicotine application on the sEPSCs (Left). Holding potential was 70 mV
in voltage clamp mode. Right shows the cumulative curves of frequency and amplitude before and after application of 10 mol/l nicotine. Nicotine increased
the frequency of sEPSCs significantly assessed by Kolmogorov-Smimov analysis (P  0.0001). (C). Representative traces and cumulative curves show that 300 nmol/l
nicotine application increased the frequency of sEPSCs. (D). Bar graphs show the mean sEPSC frequency and amplitude fold increase after 300 nmol/l nicotine
application in WT and Lynx2/ mice. The response to nicotine was significantly more enhanced in Lynx2/ mice than in WT controls (WT: 5 mice, 11 cells;
Lynx2/: 5 mice, 11 cells). (*, P  0.05.)








nAChR subunits and Flag-tagged Grid2 receptor. Two days after transfection,
cells were washed, harvested, and used for IP as described (10).
Oocyte Electrophysiology. The cRNAs for Lynx1, Lynx2, Ly6h and nAChR sub-
units (4, 2, 4, 1, 2,  and ) were synthesized with T7 or SP6 RNA
polymerases (mMESSAGE mMACHINE, Ambion, Austin, TX) through in vitro
transcription. To quantify the yield of the synthesized transcripts, they were
analyzed by agarose gel electrophoresis. Xenopus oocytes were injected with
0.5 ng of the cRNA encoding each nAChR subunit and with 3 ng of LYNX1,
LYNX2, or LY6H (20 nl per oocyte). The electrophysiological recordings were
done as described (10) .
Open-Field Exploration Test. Experimenter was blind as to the genotype of the
mice in the behavior experiments. Procedures for the behavior tests were
approved by the Institutional Animal Care and Use Committee of the Rock-
efeller University. Animals were group housed in a 12 hour dark, 12 hour light
cycle, and tests were performed during the light phase. For all behavior
studies the controls were age matched C57BL/6 WT mice. The behavior tests
were performed on mice between 13 and 16 weeks of age. Four mice were
tested every session in separate arenas. The containers were cleaned with
isopropanol before each session. The test room was illuminated with a
60-W bulb in the middle of the room. Ethovision software and equipment
(Noldus) were used for open field exploration test. The camera and soft-
ware distinguished the black test mice from the white background. The
computer recorded the movement patterns of the test mice for 20 minutes
and then calculated the reported behaviors.
Light-Dark Box Test. The test apparatus (45  25  30 cm) consisted of light and
dark compartments separated by an open door. The dark compartment was
one third of the total size and had a lid on top. The light compartment was
illuminated by a 60-W bulb. Mice behavior was recorded for 10 minutes, and
the time spent in each compartment and number of transitions between
compartments was analyzed by Ethovision software.
Social Interaction Test. The apparatus for social interaction test was built based
on the design described previously (18). (See SI Materials and Methods for
details.)
Passive Avoidance Test. PACS-30 Passive/Active avoidance box from Columbus
Instruments (USA) was used for these studies. (See SI Materials and Methods
for details.)
Fear Conditioning Test. A conditioning chamber from Med Associates was used
for fear conditioning tests as described (12). On training day, the mice were
presented with two tones (30 seconds, 80 db) paired with foot shocks (2
seconds, 0.5 mA). (See SI Materials and Methods for details.)
Statistical Analysis of Behavior Tests. GraphPad Prism version 4.03 for Windows
(GraphPad Software, San Diego, CA) was used for statistical analysis of the
data. Two-tailed Student t tests were used for analyzing the open field
exploration behavior, hot-plate test, olfaction test, elevated plus-maze test,
light-dark box test, social interaction test and baseline anxiety measurements
of passive avoidance test. To analyze data from the passive avoidance learning
and fear conditioning tests, two-way analysis of variance with Bonferroni’s
post tests was used.
Whole Cell Recordings in Medial Prefrontal Cortex Slices. Medial prefrontal
cortex brain slices were prepared from 4–5-week-old C57BL/6 and Lynx2/
mice in adherence with protocols approved by the Rockefeller University
Animal Care and Use Committee. (See SI Materials and Methods for details.)
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